Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening
Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage o...
Uloženo v:
| Vydáno v: | BMC cancer Ročník 20; číslo 1; s. 396 - 13 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
06.05.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1471-2407, 1471-2407 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening.
Methods
The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed.
Results
In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (
p
= 0.002;
p
= 0.01) and specificity (
p
= 0.01;
p
= 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types.
Conclusions
The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. |
|---|---|
| AbstractList | Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. Methods The CLART[R] HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed [greater than or equai to]CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed. Results In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types. Conclusions The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. Methods The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed. Results In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity ( p = 0.002; p = 0.01) and specificity ( p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types. Conclusions The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. The CLART[R] HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed [greater than or equai to]CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed. In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types. The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. Abstract Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. Methods The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed. Results In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types. Conclusions The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening.BACKGROUNDTo ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening.The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed.METHODSThe CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed.In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types.RESULTSIn SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types.The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples.CONCLUSIONSThe CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. Methods The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed. Results In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types. Conclusions The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1184 SurePath and 1169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed. In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR = 0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR = 1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p = 0.002; p = 0.01) and specificity (p = 0.01; p = 0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types. The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples. |
| ArticleNumber | 396 |
| Audience | Academic |
| Author | Lagheden, Camilla Ejegod, Ditte Møller Boada, Elia Alcañiz Bonde, Jesper Bhatia, Ramya Sundström, Karin Pedersen, Helle Cuschieri, Kate Dillner, Joakim Josë, F. Xavier Bosch Cortés, Javier |
| Author_xml | – sequence: 1 givenname: Ditte Møller surname: Ejegod fullname: Ejegod, Ditte Møller email: ditte.ejegod@regionh.dk, Ditte.ejegod@regionh.dk organization: Molecular Pathology Laboratory, Department of Pathology, Hvidovre Hospital, Copenhagen University Hospital – sequence: 2 givenname: Camilla surname: Lagheden fullname: Lagheden, Camilla organization: Department of Laboratory Medicine, Karolinska Institutet, and Karolinska University Laboratory, Karolinska University Hospital – sequence: 3 givenname: Ramya surname: Bhatia fullname: Bhatia, Ramya organization: HPV Research Group, University of Edinburgh, Queen’s Medical Research Institute – sequence: 4 givenname: Helle surname: Pedersen fullname: Pedersen, Helle organization: Molecular Pathology Laboratory, Department of Pathology, Hvidovre Hospital, Copenhagen University Hospital – sequence: 5 givenname: Elia Alcañiz surname: Boada fullname: Boada, Elia Alcañiz organization: HPV Research Group, University of Edinburgh, Queen’s Medical Research Institute – sequence: 6 givenname: Karin surname: Sundström fullname: Sundström, Karin organization: Department of Laboratory Medicine, Karolinska Institutet, and Karolinska University Laboratory, Karolinska University Hospital – sequence: 7 givenname: Javier surname: Cortés fullname: Cortés, Javier organization: Spanish Society of Obstetrics and Gynecology – sequence: 8 givenname: F. Xavier Bosch surname: Josë fullname: Josë, F. Xavier Bosch organization: Cancer Epidemiology Research Program, Catalan Institute of Oncology, Granvia de L’Hospitalet 199-203 – sequence: 9 givenname: Kate surname: Cuschieri fullname: Cuschieri, Kate organization: Scottish HPV Reference Laboratory, Department of Laboratory Medicine, Royal Infirmary of Edinburgh – sequence: 10 givenname: Joakim surname: Dillner fullname: Dillner, Joakim organization: Department of Laboratory Medicine, Karolinska Institutet, and Karolinska University Laboratory, Karolinska University Hospital – sequence: 11 givenname: Jesper surname: Bonde fullname: Bonde, Jesper organization: Molecular Pathology Laboratory, Department of Pathology, Hvidovre Hospital, Copenhagen University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32375689$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k1Fq3DAQhk1JaZJtL9CHIiiU9sGpZFu2_FJYlrYJBBqStK9Clse2gixtJHlpLtVD9Bq9TLW7aZINJRhkW_7-fzTjmcNkz1gDSfKa4CNCWPnRk4wxmuIMp7hkjKX4WXJAioqkWYGrvQfP-8mh91cYk4ph9iLZz7O8oiWrD5I_C62MkkKjldCqFUFZg2yHuklr1IOx4WapTI8Wp_Pzy9-_0PHZj-ICCe_FDYrkxeTgTIQBCdOiy0GZMwdLJK3WIAO0yEsHYNYGXoxLDR4JKa1r1zvBojAAUiaAM5vA8RT9pFqIR4pkZx0aplEYtBRLpbUdxUq5yaMAPiAH15NyMIIJW1SCW20SuYv5MnneCe3h1e19lnz_8vlycZyefvt6spifprIiOKRMVEVT46KrSUcpwxlrMaNSNm0GhILsatp2Da4wg6Lp6kwUTdNgltOMUllleT5LTra-rRVXfOnUKNwNt0LxzYZ1PRcuKKmBC9xALcu4tqzAwOoyrxtZxPcOaENp9Pq09VpOzQitjOk5oXdMd78YNfDerniV4byOp5kl728NnL2eYqX4qLwErYUBO3me5XXNclKRday3j9ArO8VfoSNV4KIgFFflPdWLmIAynY1x5dqUz8usKnJK4zJLjv5DxauFUcnYt52K-zuCDzuCyAT4GXoxec9PLs532XcP2AGEDoO3elr3jN8F3zys3l3Z_vV7BLItIJ313kF3hxDM10PFt0PF41DxzVBxHEXskUiqsGnYmKPST0vzrdTHOKYHd1_iJ1R_AZ53Oe8 |
| CitedBy_id | crossref_primary_10_1186_s12905_023_02215_4 crossref_primary_10_1186_s12985_025_02767_x crossref_primary_10_1016_j_jmoldx_2021_12_009 crossref_primary_10_3390_pathogens12070908 crossref_primary_10_1016_j_cmi_2021_04_031 crossref_primary_10_3390_v14050893 crossref_primary_10_1016_j_jcv_2023_105638 crossref_primary_10_1186_s12879_020_05663_7 crossref_primary_10_1016_j_jviromet_2021_114118 crossref_primary_10_1128_spectrum_00332_24 crossref_primary_10_1136_jclinpath_2021_207864 |
| Cites_doi | 10.1128/JCM.02716-14 10.1016/j.ygyno.2015.06.040 10.3390/ijms19092704 10.1002/ijc.29374 10.1007/s10552-013-0320-z 10.1080/14737159.2019.1613890 10.1097/LGT.0000000000000494 10.1128/JCM.00633-13 10.1186/1471-2334-14-413 10.1016/j.ygyno.2018.04.007 10.1016/j.virol.2013.07.015 10.1128/JCM.01517-13 10.1016/j.vaccine.2012.06.095 10.1016/j.jcv.2015.10.023 10.1371/journal.pone.0059765 10.7326/M15-2735 10.1016/j.cmi.2015.04.015 10.1002/ijc.32291 10.1128/JCM.00508-16 10.1016/j.jmoldx.2016.10.003 10.1309/AJCPHH1B0COCBGOM 10.1016/j.ejca.2015.06.001 10.1002/ijc.29085 10.1002/path.4424 10.1002/ijc.30375 10.1038/s41416-018-0053-6 10.1186/s12985-018-0965-z 10.1002/ijc.24010 10.1128/JCM.00759-13 10.1002/ijc.25396 10.1016/j.pvr.2017.04.005 10.1093/jnci/dji187 10.1128/JCM.02007-08 10.1128/JCM.01231-12 10.1016/j.jcv.2017.12.001 10.1128/JCM.01743-09 10.1136/jclinpath-2011-200152 10.1128/JCM.03195-13 10.1016/S0140-6736(13)62218-7 10.1128/JCM.05552-11 10.4172/2161-0703.S3-003 10.1128/JCM.44.2.504-512.2006 10.1016/j.jcv.2016.01.009 10.1016/j.jcv.2018.09.005 10.1136/bmjopen-2016-014788 10.1016/j.jmoldx.2013.04.002 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-020-06888-0 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_a0be9c60bed840e89639bc40befe5b55 PMC7203972 A627435574 32375689 10_1186_s12885_020_06888_0 |
| Genre | Validation Study Journal Article |
| GeographicLocations | Denmark Sweden Spain |
| GeographicLocations_xml | – name: Denmark – name: Sweden – name: Spain |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c710t-8a74b904f91f558028d085ccbd2e15ecf95dfb0708e4bf92a4bbb0835255c7233 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000533952600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 14 19:03:33 EDT 2025 Tue Nov 04 01:54:26 EST 2025 Sun Nov 09 10:06:19 EST 2025 Tue Oct 07 05:24:15 EDT 2025 Tue Nov 11 10:24:04 EST 2025 Tue Nov 04 18:06:13 EST 2025 Thu Nov 13 15:08:07 EST 2025 Thu May 22 21:20:16 EDT 2025 Mon Jul 21 06:08:11 EDT 2025 Sat Nov 29 06:41:54 EST 2025 Tue Nov 18 20:49:34 EST 2025 Sat Sep 06 07:18:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c710t-8a74b904f91f558028d085ccbd2e15ecf95dfb0708e4bf92a4bbb0835255c7233 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/docview/2404415076?pq-origsite=%requestingapplication% |
| PMID | 32375689 |
| PQID | 2404415076 |
| PQPubID | 44074 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a0be9c60bed840e89639bc40befe5b55 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7203972 proquest_miscellaneous_2399831715 proquest_journals_2404415076 gale_infotracmisc_A627435574 gale_infotracacademiconefile_A627435574 gale_incontextgauss_ISR_A627435574 gale_healthsolutions_A627435574 pubmed_primary_32375689 crossref_primary_10_1186_s12885_020_06888_0 crossref_citationtrail_10_1186_s12885_020_06888_0 springer_journals_10_1186_s12885_020_06888_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-06 |
| PublicationDateYYYYMMDD | 2020-05-06 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | MD Krevolin (6888_CR47) 2017; 19 6888_CR38 S Preisler (6888_CR48) 2013; 8 L Xu (6888_CR41) 2018; 98 M Iacobellis (6888_CR13) 2018; 15 J Viti (6888_CR39) 2018; 108 PM Agreda (6888_CR44) 2013; 51 6888_CR31 D Bzhalava (6888_CR20) 2013; 445 M Schiffman (6888_CR28) 2016; 139 L Xu (6888_CR32) 2019; 19 D Ejegod (6888_CR16) 2016; 54 A Boers (6888_CR6) 2014; 52 G Ronco (6888_CR2) 2014; 383 M Schmitt (6888_CR35) 2006; 44 CB Moelans (6888_CR43) 2011; 136 M Arbyn (6888_CR5) 2015; 21 M Chernesky (6888_CR45) 2017; 3 A Soderlund-Strand (6888_CR36) 2009; 47 DA Heideman (6888_CR9) 2013; 51 MJ Khan (6888_CR21) 2005; 97 6888_CR23 MH Stoler (6888_CR17) 2018; 149 6888_CR19 N Li (6888_CR22) 2011; 128 V Smelov (6888_CR29) 2015; 136 6888_CR15 M Schiffman (6888_CR30) 2015; 138 AT Hesselink (6888_CR10) 2014; 52 SK Kjaer (6888_CR27) 2014; 25 LT Thomsen (6888_CR26) 2015; 137 CE Depuydt (6888_CR7) 2012; 50 Group IMw (6888_CR25) 2007 M Poljak (6888_CR3) 2016; 76 CJ Meijer (6888_CR4) 2009; 124 M Rebolj (6888_CR46) 2013; 15 AT Hesselink (6888_CR11) 2013; 51 M Arbyn (6888_CR33) 2017; 166 C Lagheden (6888_CR34) 2018; 118 AT Hesselink (6888_CR12) 2016; 76 DA Heideman (6888_CR8) 2011; 49 M Arbyn (6888_CR1) 2012; 30 M Arbyn (6888_CR18) 2014; 234 CB Moelans (6888_CR42) 2011; 64 H Lamin (6888_CR37) 2017; 7 AT Hesselink (6888_CR14) 2010; 48 J Bonde (6888_CR49) 2014; 14 B Serrano (6888_CR24) 2015; 51 6888_CR40 |
| References_xml | – volume: 52 start-page: 4391 year: 2014 ident: 6888_CR6 publication-title: J Clin Microbiol doi: 10.1128/JCM.02716-14 – volume: 138 start-page: 573 year: 2015 ident: 6888_CR30 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.06.040 – ident: 6888_CR40 doi: 10.3390/ijms19092704 – volume: 137 start-page: 193 year: 2015 ident: 6888_CR26 publication-title: Int J Cancer doi: 10.1002/ijc.29374 – volume: 25 start-page: 179 year: 2014 ident: 6888_CR27 publication-title: Cancer Causes Control doi: 10.1007/s10552-013-0320-z – volume: 19 start-page: 543 year: 2019 ident: 6888_CR32 publication-title: Expert Rev Mol Diagn doi: 10.1080/14737159.2019.1613890 – ident: 6888_CR23 doi: 10.1097/LGT.0000000000000494 – volume: 51 start-page: 2409 year: 2013 ident: 6888_CR11 publication-title: J Clin Microbiol doi: 10.1128/JCM.00633-13 – volume: 14 start-page: 413 year: 2014 ident: 6888_CR49 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-14-413 – volume: 149 start-page: 498 year: 2018 ident: 6888_CR17 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.04.007 – volume: 445 start-page: 224 year: 2013 ident: 6888_CR20 publication-title: Virology doi: 10.1016/j.virol.2013.07.015 – volume: 51 start-page: 3653 year: 2013 ident: 6888_CR9 publication-title: J Clin Microbiol doi: 10.1128/JCM.01517-13 – volume: 30 start-page: F88 issue: Suppl 5 year: 2012 ident: 6888_CR1 publication-title: Vaccine doi: 10.1016/j.vaccine.2012.06.095 – volume: 76 start-page: S3 issue: Suppl 1 year: 2016 ident: 6888_CR3 publication-title: J Clin Virol doi: 10.1016/j.jcv.2015.10.023 – volume: 8 start-page: e59765 year: 2013 ident: 6888_CR48 publication-title: PLoS One doi: 10.1371/journal.pone.0059765 – volume: 166 start-page: 118 year: 2017 ident: 6888_CR33 publication-title: Ann Intern Med doi: 10.7326/M15-2735 – volume: 21 start-page: 817 year: 2015 ident: 6888_CR5 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2015.04.015 – ident: 6888_CR19 doi: 10.1002/ijc.32291 – volume: 54 start-page: 2267 year: 2016 ident: 6888_CR16 publication-title: J Clin Microbiol doi: 10.1128/JCM.00508-16 – volume: 19 start-page: 288 year: 2017 ident: 6888_CR47 publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2016.10.003 – volume: 136 start-page: 548 year: 2011 ident: 6888_CR43 publication-title: Am J Clin Pathol doi: 10.1309/AJCPHH1B0COCBGOM – volume: 51 start-page: 1732 year: 2015 ident: 6888_CR24 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.06.001 – volume: 136 start-page: 1171 year: 2015 ident: 6888_CR29 publication-title: Int J Cancer doi: 10.1002/ijc.29085 – volume: 234 start-page: 431 year: 2014 ident: 6888_CR18 publication-title: J Pathol doi: 10.1002/path.4424 – volume: 139 start-page: 2606 year: 2016 ident: 6888_CR28 publication-title: Int J Cancer doi: 10.1002/ijc.30375 – volume: 118 start-page: 1377 year: 2018 ident: 6888_CR34 publication-title: Br J Cancer doi: 10.1038/s41416-018-0053-6 – volume: 15 start-page: 48 year: 2018 ident: 6888_CR13 publication-title: Virol J doi: 10.1186/s12985-018-0965-z – volume: 124 start-page: 516 year: 2009 ident: 6888_CR4 publication-title: Int J Cancer doi: 10.1002/ijc.24010 – volume: 51 start-page: 2702 year: 2013 ident: 6888_CR44 publication-title: J Clin Microbiol doi: 10.1128/JCM.00759-13 – volume: 128 start-page: 927 year: 2011 ident: 6888_CR22 publication-title: Int J Cancer doi: 10.1002/ijc.25396 – volume: 3 start-page: 155 year: 2017 ident: 6888_CR45 publication-title: Papillomavirus Res doi: 10.1016/j.pvr.2017.04.005 – volume: 97 start-page: 1072 year: 2005 ident: 6888_CR21 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji187 – volume: 47 start-page: 541 year: 2009 ident: 6888_CR36 publication-title: J Clin Microbiol doi: 10.1128/JCM.02007-08 – volume: 50 start-page: 4073 year: 2012 ident: 6888_CR7 publication-title: J Clin Microbiol doi: 10.1128/JCM.01231-12 – ident: 6888_CR38 – volume: 98 start-page: 37 year: 2018 ident: 6888_CR41 publication-title: J Clin Virol doi: 10.1016/j.jcv.2017.12.001 – volume: 48 start-page: 797 year: 2010 ident: 6888_CR14 publication-title: J Clin Microbiol doi: 10.1128/JCM.01743-09 – volume-title: IARCH monographs on the evaluation of Carconogenic risks of humans year: 2007 ident: 6888_CR25 – volume: 64 start-page: 960 year: 2011 ident: 6888_CR42 publication-title: J Clin Pathol doi: 10.1136/jclinpath-2011-200152 – volume: 52 start-page: 890 year: 2014 ident: 6888_CR10 publication-title: J Clin Microbiol doi: 10.1128/JCM.03195-13 – volume: 383 start-page: 524 year: 2014 ident: 6888_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(13)62218-7 – volume: 49 start-page: 3983 year: 2011 ident: 6888_CR8 publication-title: J Clin Microbiol doi: 10.1128/JCM.05552-11 – ident: 6888_CR15 doi: 10.4172/2161-0703.S3-003 – volume: 44 start-page: 504 year: 2006 ident: 6888_CR35 publication-title: J Clin Microbiol doi: 10.1128/JCM.44.2.504-512.2006 – volume: 76 start-page: 36 year: 2016 ident: 6888_CR12 publication-title: J Clin Virol doi: 10.1016/j.jcv.2016.01.009 – volume: 108 start-page: 38 year: 2018 ident: 6888_CR39 publication-title: J Clin Virol doi: 10.1016/j.jcv.2018.09.005 – volume: 7 start-page: e014788 year: 2017 ident: 6888_CR37 publication-title: BMJ Open doi: 10.1136/bmjopen-2016-014788 – volume: 15 start-page: 670 year: 2013 ident: 6888_CR46 publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2013.04.002 – ident: 6888_CR31 |
| SSID | ssj0017808 |
| Score | 2.353939 |
| Snippet | Background
To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in... To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with... Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in... Abstract Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 396 |
| SubjectTerms | Adult Age Aged Algorithms Biobanks Biomedical and Life Sciences Biomedicine Cancer Research Cancer screening Cellular biology Cervical cancer Cervical Intraepithelial Neoplasia - diagnosis Cervical Intraepithelial Neoplasia - epidemiology Cervical Intraepithelial Neoplasia - genetics Cervical Intraepithelial Neoplasia - virology Cervix Deoxyribonucleic acid DNA DNA, Viral - analysis DNA, Viral - genetics Early Detection of Cancer - methods Epidemiology Female Follow-Up Studies Genotype Genotypes Genotyping Health Promotion and Disease Prevention Human papillomavirus Humans Laboratories Medical screening Medical tests Medicine/Public Health Middle Aged Oncology Papillomaviridae - genetics Papillomaviridae - isolation & purification Papillomavirus Papillomavirus infections Papillomavirus Infections - complications Papillomavirus Infections - virology Population Practice Guidelines as Topic - standards prevention and public health Prognosis Research Article Sensitivity analysis Specimen Handling - methods Surgical Oncology Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - genetics Uterine Cervical Neoplasms - virology Women's health Womens health Young Adult |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQhRAXxD-BAgYhcYCo2cSJnWOpqIoE1YoF1JtlO3YbaUlWyaZSX4qH4DV4GWacbNgUARcuK20y-bO_TL6xx98Q8oKnqYEowIUzx3jIsrQIhcmjkFkVuXymuLDaF5vgx8fi5CSfb5X6wpywXh64b7g9FWmbmwx-C4hFrADA5Now-O9sqlOvXgqsZxNMDfMHXERis0RGZHsteGGBK5H7IisijCafIa_W_7tP3vooXU6YvDRr6j9GhzfJjYFF0v3-7m-RK7a6Ta59GObJ75Afg9znkgKQyr5sEq0dxcF2irKs6wtcJ0UP3gOf_f6NHs2_sAUFHq0uKFguusbOgRpSVRUUK3vOG7uiCBlwj7ag4Gog_MUTtArVhVuqDEaxuGVdU-CUtNweaaSnHappYYY9BZJMfWFAulKrcrmsv6rzsulaCpx3TRuLmcl-yLI3Nd6XwSnGa94lnw_ffjo4CocyDqEB-rIOheJM5xGDrndpKoDQFMDzjNFFbGepNS5PC6fB9QjLtMtjxbTWnhkCjnicJPfITlVX9gGhGS9sopyNXcKYUlYlhXYq5QVXgJDMBGS26VVpBo1zLLWxlD7WEZnskSABCdIjQUYBeTUes-oVPv5q_QbBMlqiOrffAJiVA2blvzAbkKcINdkvdR19jNzHQkhAADkLyHNvgQodFaYAnaqubeW7xceJ0cvByNXwlEYNKyqgrVDUa2K5O7EEF2KmuzeYl4MLayVQPYy1I54F5Nm4G4_EtLzK1h3YAL0VwEBn8Ej3-1dkbJkkTniaiTwgfPLyTJpuuqcqz7zAOaYG5DwOyOvNa_brtv7cNQ__R9c8Itdj7ybAW2S7ZGfddPYxuWrO12XbPPFO5iddxYYl priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVQQYgX7pdAAYOQeICo2dzsPJaKqkhQrbpQ9c2yHXuJtCSrXCr1p_gIfoOfYcbJhqZcJHjceJxN4pnjM_Z4hpAXLEk0eAHWn9mY-XGa5D7XWeDHRgY2m0nGjXLFJtjhIT85yebDobBmE-2-2ZJ0SO3Mmqc7DSApx9PEfaEU7oOjfhmmO47meLQ4HvcOGA_45njMb_tNpiCXqf9XPD43IV0MlrywY-omov0b__cKN8n1gXjS3V5TbpFLprxNrn4YttbvkO9DhtAVBd0r-kpLtLIU1-cpZnJtz_BoFd17DxT421d6MD-OFxSotzyjILnoajMHNkllmVMsBjqvzZqilgGimpwCOoHHjDdoJCYkbqjU6PjilbaiQENpcX5xki47TMCFQfkUeDV1tQTpWq6L1ar6Ik-Lumso0OSW1gaDmd0qZy-qHfzBLcb_vEs-7b_9uHfgD5UffA2Mp_W5ZLHKghi0xSYJBw6UAzXUWuWhmSVG2yzJrQK04iZWNgtlrJRyZBJUj4VRdI9slVVpHhCastxE0prQRnEspZFRrqxMWM5kGqhUe2S2UQahh7ToWJ1jJZx7xFPRj5qAURNu1ETgkVdjn3WfFOSv0m9Qx0ZJTOjtLlT1Ugz4IGSgTKbhiUwOLrfhgIuZ0jH8tiZRSeKRp6ihoj8dO8KS2MXaScAZWeyR504Ck3qUGDW0lF3TiHeLo4nQy0HIVvCWWg6HMOBbYR6wieT2RBJQR0-bN6YiBtRrBLBDdM8Dlnrk2diMPTGSrzRVBzLAiDmQ1hm80v3essYvE4URS1KeeYRNbG7y6aYtZfHZ5UTHaIKMhR55vbG8n4_156F5-G_ij8i10Bkv2HC6TbbaujOPyRV92hZN_cSh0A_Ymok3 priority: 102 providerName: Springer Nature |
| Title | Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening |
| URI | https://link.springer.com/article/10.1186/s12885-020-06888-0 https://www.ncbi.nlm.nih.gov/pubmed/32375689 https://www.proquest.com/docview/2404415076 https://www.proquest.com/docview/2399831715 https://pubmed.ncbi.nlm.nih.gov/PMC7203972 https://doaj.org/article/a0be9c60bed840e89639bc40befe5b55 |
| Volume | 20 |
| WOSCitedRecordID | wos000533952600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: Directory of Open Access Scholarly Resources (ROAD) customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFLVoixAb3o9AKQYhsYCombzsrFBbtWolWkUdqMrKchy7jDQkQzJTqT_FR_Ab_Az3Op60KYINm5GS3DzsOT4-tq_vJeQNSxIFowDjj0zM_DhNSp-rLPBjLQOTjSTjurDJJtjRET89zXI34dY6t8olJ1qiLmuFc-Sb0POg9Idh94fZdx-zRuHqqkuhsULWMFJZvErWtneP8uN-HYHxgC-3yvB0swU25rgjuUu2wv1g0B3ZqP1_cvOVzum64-S11VPbKe3d_d_i3CN3nBylWx1-7pMbunpAbh26BfeH5JeLGzqlgMhJl3-J1obirD3F-K7zC9xwRXc-gjD--YPu5yfxmIIglxcULMeLRuegMamsSoopQvNGzyhiD3hWlxQ4C8bR-IBWYpjilkqFw2E8M68piFM6uTplSc8WGJYLXfUpqG1qMwzSmZxNptP6mzyfNIuWgnie00aji7Od--xMlSVFeET_zkfk897up5193-WD8BXooLnPJYuLLIgBQyZJOCijEgSjUkUZ6lGilcmS0hTAYVzHhclCGRdFYSUmAJKFUfSYrFZ1pZ8SmrJSR9Lo0ERxLKWWUVkYmbCSyTQoUuWR0RIWQrlg6ZizYyrsoImnooOSACgJCyUReORdf8-sCxXyT-ttRFtviWG-7Ym6OROONYQMCp0p-CJdwkBcc2DLrFAxHBudFEnikZeIVdHtme3JSmxhRiVQkiz2yGtrgaE-KvQlOpOLthUH4-OB0VtnZGoopZJuawbUFUYHG1iuDyyBi9Tw8hLtwnFhKy6h7pFX_WW8E_37Kl0vwAZ0MgcpO4IiPenaWF8zURixJOWZR9ig9Q2qbnilmny1kdLRxyBjoUfeL9vp5Wf9_a959u9SPCe3Q8sgQCTpOlmdNwv9gtxU5_NJ22yQFXbK7C_fcGy0YSd64Cg_OMy_wNHx-OQ3AqGZxg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqFgEX3o9AoQaBOEDUbNaJnQNCpVB11YdWtEXlZBzHKSstyZLsFu2f6o_gb_BnmHEebYrorQeOm0yytjPzzYw9D0Je8CDQ4AWkbi9l3GVhkLhCR57LjPLSqKe4MLFtNsF3d8XhYTRcICdNLgyGVTaYaIE6yTXuka-C5kHTH9zud5MfLnaNwtPVpoVGxRZbZv4TXLby7eADfN-Xvr_xcX990627CrgatOnUFYqzOPIYjCQNAgH6NQGzQ-s48U0vMDqNgiSNQRKEYXEa-YrFcWwNFZgW93EDFCB_iQGzi0WyNBzsDL-05xZceKJJzRHhagnoLzADumruIlyvo_5sl4C_dcEZZXg-UPPcaa1Vghs3_7flu0Vu1OY2Xavk4zZZMNkdcnWnDii4S37XdVHHFCRuVPWXonlK8VSCYv3a6RwTyuj6Nhj-v07o5vAz26PgcKg5Bcq9WWGGYENTlSUUW6AOCzOhKFugR0xCAZONwZ0nWiosw1xSpdHdxyvTnILxTUdnt2Tp0QzLjmEqAgVvgtoOinSiJqPxOP-ujkfFrKTgHExpYTCE2-7tVqTagj68ov3Pe-TgUpb2PlnM8sw8JDTkiemr1PhpnzGljOoncaoCnnAVenGoHdJr2FDquhg89iQZS-sUilBWrCuBdaVlXek55HX7zKQqhXIh9Xvk7pYSy5jbC3lxJGtUlMqLTaRhRCYRzDMCtEEUawa_UxPEQeCQFZQNWeUEt2As17BjFFjKnDnkuaXAUiYZxkodqVlZysHepw7Rq5oozWGWWtWpJ7BWWP2sQ7ncoQSs1d3bjXTJGutLeSpaDnnW3sYnMX4xM_kMaMAPEGCq92BKDyqZblem7_d5EIrIIbwj7Z2l697JRt9sJXiMoYi475A3DS6cDuvfn-bRxbNYIdc293e25fZgd-sxue5b9AIQC5fJ4rSYmSfkij6ejsriaY1-lHy9bMT4A1Z68QA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtQwELVQQRUv3CmBQg1C4gGiZnOz81gKq1aU1YqFqm-W7dhlpSVZJdlK_Sk-gt_gZ5hxsqEpFwnxuPE4G9sz4zP2XAh5zpJEgxVg_ZGNmR-nSe5znQV-bGRgs5Fk3ChXbIJNJvzkJJteiOJ33u7rK8k2pgGzNBXN7jK3rYjzdLcGrcoxsrgtmsJ9MNqvxlg0CO312XF_j8B4wNehMr_tN9iOXNb-X3Xzhc3psuPkpdtTtymNb_7_cG6RGx0gpXstB90mV0xxh2y-767c75LvXebQBQWenLcVmGhpKZ7bU8zw2pxjyBXdPwJo_O0rPZgexzMKkFyeU6CcrSozBZRJZZFTLBI6rcySIveBpjU5Ba0FljS-oJaYqLimUqNBjE-akgI8pfOLh5b0dIWJudBZnwLepq7GIF3K5XyxKL_Is3m1qinA54ZWBp2c3elnS6qdWoRX9P95j3wav_24f-B3FSF8DUio8blkscqCGLjIJgkHbJQDZNRa5aEZJUbbLMmtAi3GTaxsFspYKeVAJrAkC6PoPtkoysI8IDRluYmkNaGN4lhKI6NcWZmwnMk0UKn2yGjNGEJ36dKxasdCOLOJp6JdNQGrJtyqicAjL_s-yzZZyF-pXyO_9ZSY6Ns9KKtT0ekNIQNlMg1fZHIwxQ0HfZkpHcNvaxKVJB7ZQW4VbdRsr67EHtZUAizJYo88cxSY7KNAb6JTuaprcTj7MCB60RHZEkapZRecAXOF-cEGlNsDStBGeti8FhvRacNaAGpEsz1gqUee9s3YEz38ClOugAaQMgcwO4IhbbVS1s9MFEYsSXnmETaQv8HUDVuK-WeXKx29DDIWeuTVWgp_ftafl-bhv5HvkM3pm7E4Opy8e0Suh06OQZzTbbLRVCvzmFzTZ828rp445fQDthSU_w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+validation+of+full+genotyping+CLART%5BR%5D+HPV4S+assay+on+SurePath+and+ThinPrep+collected+screening+samples+according+to+the+international+guidelines+for+human+papillomavirus+test+requirements+for+cervical+screening&rft.jtitle=BMC+cancer&rft.au=Ejegod%2C+Ditte+Maller&rft.au=Lagheden%2C+Camilla&rft.au=Bhatia%2C+Ramya&rft.au=Pedersen%2C+Helle&rft.date=2020-05-06&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-020-06888-0&rft.externalDocID=A627435574 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |